• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

SEOM-SOGUG尿路上皮癌临床指南(2025年)

SEOM-SOGUG clinical guideline for urothelial cancer (2025).

作者信息

Puente Javier, Rodríguez-Vida Alejo, Sevillano Elena, Estévez Sergio Vázquez, Fernández Carlos Álvarez, Chirivella Isabel, Climent Miguel Ángel, Fernández Ovidio, de Liaño Alfonso Gómez, Valderrama Begoña P

机构信息

Medical Oncology Department, Hospital Universitario Clínico San Carlos, Madrid, Spain.

Medical Oncology Department, Hospital del Mar, Barcelona, Spain.

出版信息

Clin Transl Oncol. 2025 Sep 17. doi: 10.1007/s12094-025-04045-2.

DOI:10.1007/s12094-025-04045-2
PMID:40960583
Abstract

This clinical guideline provides evidence-based recommendations for the diagnosis, staging, and management of bladder cancer across all disease stages. In these guidelines (updated in 2025), we summarize current evidence and available therapies for the medical management of urothelial cancer.

摘要

本临床指南为膀胱癌在所有疾病阶段的诊断、分期及管理提供了循证建议。在这些指南(于2025年更新)中,我们总结了尿路上皮癌医学管理的当前证据及可用疗法。

相似文献

1
SEOM-SOGUG clinical guideline for urothelial cancer (2025).SEOM-SOGUG尿路上皮癌临床指南(2025年)
Clin Transl Oncol. 2025 Sep 17. doi: 10.1007/s12094-025-04045-2.
2
Diagnosis and Management of Upper Tract Urothelial Carcinoma: A Review.上尿路尿路上皮癌的诊断与管理:综述
Cancers (Basel). 2025 Jul 25;17(15):2467. doi: 10.3390/cancers17152467.
3
Unmet Need in Non-muscle-invasive Bladder Cancer Failing Bacillus Calmette-Guérin Therapy: A Systematic Review and Cost-effectiveness Analyses from the International Bladder Cancer Group.卡介苗治疗失败的非肌层浸润性膀胱癌的未满足需求:国际膀胱癌小组的系统评价和成本效益分析
Eur Urol Oncol. 2025 Feb;8(1):216-229. doi: 10.1016/j.euo.2024.10.012. Epub 2024 Nov 15.
4
Intravesical electromotive drug administration for non-muscle invasive bladder cancer.非肌层浸润性膀胱癌的膀胱内电动药物给药
Cochrane Database Syst Rev. 2017 Sep 12;9(9):CD011864. doi: 10.1002/14651858.CD011864.pub2.
5
Impact of upper tract urothelial carcinoma on response to BCG in patients with non-muscle-invasive bladder cancer.上尿路尿路上皮癌对非肌肉浸润性膀胱癌患者对卡介苗反应的影响。
BJU Int. 2021 Nov;128(5):568-574. doi: 10.1111/bju.15344. Epub 2021 Feb 15.
6
Roles for epigenetic and other biomarkers in upper tract urothelial carcinoma diagnosis and surveillance.表观遗传学及其他生物标志物在上尿路尿路上皮癌诊断和监测中的作用。
Curr Probl Cancer. 2025 Jul 4;58:101222. doi: 10.1016/j.currproblcancer.2025.101222.
7
Oncologic Outcomes of Kidney-sparing Surgery Versus Radical Nephroureterectomy for Upper Tract Urothelial Carcinoma: A Systematic Review by the EAU Non-muscle Invasive Bladder Cancer Guidelines Panel.保留肾单位手术与根治性肾输尿管切除术治疗上尿路上皮癌的肿瘤学结局:EAU 非肌肉浸润性膀胱癌指南小组的系统评价。
Eur Urol. 2016 Dec;70(6):1052-1068. doi: 10.1016/j.eururo.2016.07.014. Epub 2016 Jul 28.
8
The impact of a multidisciplinary approach on treatment decisions and outcomes in urothelial carcinoma: A systematic review.多学科方法对尿路上皮癌治疗决策和结果的影响:一项系统综述。
Actas Urol Esp (Engl Ed). 2025 Jun;49(5):501718. doi: 10.1016/j.acuroe.2025.501718. Epub 2025 Feb 12.
9
ISCL/EORTC-CLTG/USCLC recommendations for the diagnosis, staging and treatment of early-stage paediatric mycosis fungoides: a modified Delphi consensus. Part one: diagnosis and staging.国际皮肤淋巴瘤学会/欧洲肿瘤内科学会儿童蕈样肉芽肿协作组/美国皮肤淋巴瘤协作组关于儿童早期蕈样肉芽肿诊断、分期及治疗的建议:改良德尔菲共识。第一部分:诊断与分期
Br J Dermatol. 2025 Aug 18;193(3):405-414. doi: 10.1093/bjd/ljaf199.
10
Immunotherapy for advanced or metastatic urothelial carcinoma.晚期或转移性尿路上皮癌的免疫治疗。
Cochrane Database Syst Rev. 2023 Oct 9;10(10):CD013774. doi: 10.1002/14651858.CD013774.pub2.

本文引用的文献

1
Standard or Extended Lymphadenectomy for Muscle-Invasive Bladder Cancer.标准或扩大淋巴结切除术治疗肌层浸润性膀胱癌。
N Engl J Med. 2024 Oct 3;391(13):1206-1216. doi: 10.1056/NEJMoa2401497.
2
Adjuvant Nivolumab in High-Risk Muscle-Invasive Urothelial Carcinoma: Expanded Efficacy From CheckMate 274.高危肌肉浸润性尿路上皮癌的辅助纳武利尤单抗治疗:CheckMate 274研究的疗效扩展
J Clin Oncol. 2025 Jan;43(1):15-21. doi: 10.1200/JCO.24.00340. Epub 2024 Oct 11.
3
Perioperative Durvalumab with Neoadjuvant Chemotherapy in Operable Bladder Cancer.
可手术膀胱癌新辅助化疗联合围手术期 durvalumab 治疗。
N Engl J Med. 2024 Nov 14;391(19):1773-1786. doi: 10.1056/NEJMoa2408154. Epub 2024 Sep 15.
4
Adjuvant Pembrolizumab versus Observation in Muscle-Invasive Urothelial Carcinoma.辅助性帕博利珠单抗对比观察用于肌层浸润性尿路上皮癌
N Engl J Med. 2025 Jan 2;392(1):45-55. doi: 10.1056/NEJMoa2401726. Epub 2024 Sep 15.
5
Urachal and Nonurachal Adenocarcinomas of the Urinary Bladder: A Comprehensive Genomic Profiling Study.膀胱脐尿管和非脐尿管腺癌的全面基因组分析研究。
JCO Precis Oncol. 2024 Aug;8:e2400200. doi: 10.1200/PO.24.00200.
6
Mismatch repair deficiency and microsatellite instability in urothelial carcinoma: a systematic review and meta-analysis.尿路上皮癌中的错配修复缺陷与微卫星不稳定性:一项系统评价与荟萃分析
BMJ Oncol. 2024 Jan;3(1). doi: 10.1136/bmjonc-2024-000335. Epub 2024 Apr 30.
7
Trimodal therapy vs radical cystectomy in patients with muscle-invasive bladder cancer: a systematic review and meta-analysis of comparative studies.多模式治疗与根治性膀胱切除术治疗肌层浸润性膀胱癌的比较:系统评价和荟萃分析。
BJU Int. 2024 Nov;134(5):684-695. doi: 10.1111/bju.16366. Epub 2024 Apr 15.
8
Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.2022 年全球癌症统计数据:全球 185 个国家和地区 36 种癌症的发病率和死亡率全球估计数。
CA Cancer J Clin. 2024 May-Jun;74(3):229-263. doi: 10.3322/caac.21834. Epub 2024 Apr 4.
9
Enfortumab Vedotin and Pembrolizumab in Untreated Advanced Urothelial Cancer.恩福妥单抗Vedotin 联合帕博利珠单抗治疗未经治疗的晚期尿路上皮癌。
N Engl J Med. 2024 Mar 7;390(10):875-888. doi: 10.1056/NEJMoa2312117.
10
Improved Disease-Free Survival With Adjuvant Chemotherapy After Nephroureterectomy for Upper Tract Urothelial Cancer: Final Results of the POUT Trial.肾输尿管切除术辅助化疗提高上尿路上皮癌无病生存率:POUT 试验的最终结果。
J Clin Oncol. 2024 May 1;42(13):1466-1471. doi: 10.1200/JCO.23.01659. Epub 2024 Feb 13.